[go: up one dir, main page]

WO1996033279A3 - Repertoire cloning process, products derived therefrom and uses for said products - Google Patents

Repertoire cloning process, products derived therefrom and uses for said products Download PDF

Info

Publication number
WO1996033279A3
WO1996033279A3 PCT/US1996/005114 US9605114W WO9633279A3 WO 1996033279 A3 WO1996033279 A3 WO 1996033279A3 US 9605114 W US9605114 W US 9605114W WO 9633279 A3 WO9633279 A3 WO 9633279A3
Authority
WO
WIPO (PCT)
Prior art keywords
products
cloning process
derived therefrom
repertoire cloning
products derived
Prior art date
Application number
PCT/US1996/005114
Other languages
French (fr)
Other versions
WO1996033279A2 (en
Inventor
Gregory F Okasinski
Dennis G Fry
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Priority to JP8531818A priority Critical patent/JPH11504208A/en
Priority to EP96910825A priority patent/EP0821738A2/en
Publication of WO1996033279A2 publication Critical patent/WO1996033279A2/en
Publication of WO1996033279A3 publication Critical patent/WO1996033279A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1235—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/125—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Chlamydiales (O)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A repertoire cloning process for producing mammalian monoclonal antibodies. Also provided are methods for using these monoclonal antibodies, and kits which contain these monoclonal antibodies.
PCT/US1996/005114 1995-04-21 1996-04-12 Repertoire cloning process, products derived therefrom and uses for said products WO1996033279A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP8531818A JPH11504208A (en) 1995-04-21 1996-04-12 Repertoire cloning method, product obtained therefrom and use of the product
EP96910825A EP0821738A2 (en) 1995-04-21 1996-04-12 Repertoire cloning process, products derived therefrom and uses for said products

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42679195A 1995-04-21 1995-04-21
US08/426,791 1995-04-21

Publications (2)

Publication Number Publication Date
WO1996033279A2 WO1996033279A2 (en) 1996-10-24
WO1996033279A3 true WO1996033279A3 (en) 1997-03-13

Family

ID=23692221

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/005114 WO1996033279A2 (en) 1995-04-21 1996-04-12 Repertoire cloning process, products derived therefrom and uses for said products

Country Status (4)

Country Link
EP (1) EP0821738A2 (en)
JP (1) JPH11504208A (en)
CA (1) CA2218651A1 (en)
WO (1) WO1996033279A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2446897A1 (en) 2005-01-06 2012-05-02 Novo Nordisk A/S Anti-KIR combination treatments and methods
IL296666A (en) 2005-03-23 2022-11-01 Genmab As Antibodies against 38cd for the treatment of multiple myeloma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001990A1 (en) * 1989-07-26 1991-02-21 City Of Hope Chimeric anti-cea antibody

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001990A1 (en) * 1989-07-26 1991-02-21 City Of Hope Chimeric anti-cea antibody

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
D. BURTON: "Human and mouse monoclonal antibodies by repertoire cloning.", TRENDS IN BIOTECHNOLOGY, vol. 9, no. 5, May 1991 (1991-05-01), CAMBRIDGE, GB, pages 169 - 175, XP000207982 *
I. MACLEAN ET AL.: "Production of recombinant Chlamydia trachomatis serovar D major outer membrane protein.", VACCINE, vol. 7, no. 2, April 1989 (1989-04-01), USA, pages 179 - 180, XP002024053 *
M. DUCHOSAL ET AL.: "Immunization of hu-PBL-SCID mice and the rescue of human monoclonal Fab fragments through combinatorial libraries.", NATURE, vol. 355, no. 6357, 16 January 1992 (1992-01-16), LONDON, GB, pages 258 - 262, XP002024052 *
M. POSNER ET AL.: "The generation of hybridomas secreting human monoclonal antibodies reactive with type II collagen.", HYBRIDOMA, vol. 8, no. 2, April 1989 (1989-04-01), NEW YORK, NY, USA, pages 187 - 197, XP000616479 *
N. MCCARTHY-FRANCIS ET AL.: "Kappa-chain allotypes and isotypes in the rabbit: cDNA sequences of clones encoding b9 suggest an evolutionary pathway and possible role of the interdomain disulfide bond in quantitative allotype expression.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 81, no. 5, March 1984 (1984-03-01), WASHINGTON, DC, USA, pages 1794 - 1798, XP002024054 *
P. FISCHER ET AL.: "Human monoclonal antibodies derived by repertoire cloning from immunized hu-PBL-SCID mice.", IMMUNOBIOLOGY, vol. 183, no. 3-4, October 1991 (1991-10-01), STUTTGART, GERMANY, pages 292 - 293, XP000616502 *
W. NIEDBALA ET AL.: "In vitro sensitization for human monoclonal antibody production.", IMMUNOLOGY LETTERS, vol. 35, no. 2, February 1993 (1993-02-01), AMSTERDAM, NL, pages 93 - 100, XP000616470 *

Also Published As

Publication number Publication date
WO1996033279A2 (en) 1996-10-24
EP0821738A2 (en) 1998-02-04
JPH11504208A (en) 1999-04-20
CA2218651A1 (en) 1996-10-24

Similar Documents

Publication Publication Date Title
AU1432195A (en) Process for generating specific antibodies
CA2220461A1 (en) Therapeutic compounds comprised of anti-fc receptor antibodies
AU8817391A (en) Method for the production of antibodies
AU2910197A (en) Antibodies to the ed-b domain of fibronectin, their construction and uses
CA2103059A1 (en) Method for making humanized antibodies
WO1995018826A3 (en) Purified primate ctla-8 antigens and related reagents
BR9609043A (en) Method of preparing 3 halo here 1h pyrazoles
ZA964776B (en) Mammalian cell culture process.
ZA964820B (en) Method for obtaining receptor angonist antibodies
AU1241795A (en) Anti-egf-r/anti-cd3 bispecific monoclonal antibody, method for its production and its use
EP1881064A3 (en) HCV-Anti-core monoclonal antibodies
WO1998022510A3 (en) Methods for the production of chicken monoclonal antibodies
AU5576096A (en) Method for accelerating production
EP0831098A3 (en) Intermediates and process for preparing olanzapine
EP0834559A4 (en) Process for producing l-lysine by fermentation
WO1999065947A3 (en) Monoclonal antibodies directed against the g3bp protein, and uses
AU6061896A (en) Method for waterproofing leather
AU8442391A (en) Corynebacteria integron, method of transformation of corynebacteria by said integron, and corynebacteria obtained
AU7203194A (en) Bispecific human monoclonal antibodies specific for human immunodeficiency virus
AU4221296A (en) Process for preparing an organoaluminoxy product
EP0781846A3 (en) Treponema pallidum fused antigen and assay for anti-treponema pallidum antibodies using the same fused antigen
WO1996033279A3 (en) Repertoire cloning process, products derived therefrom and uses for said products
AU698813B2 (en) Process for producing transglutaminase by microorganism
AU6108696A (en) Process for producing gm2 specific antibodies
EP0613899A3 (en) Derived from cocaine, its protein conjugate, cell line producing a monoclonal antibody, process for producing the cell line and monoclonal antibody.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Ref document number: 2218651

Country of ref document: CA

Ref country code: CA

Ref document number: 2218651

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1996 531818

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996910825

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996910825

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996910825

Country of ref document: EP